289 related articles for article (PubMed ID: 22548505)
1. Contrast agent Gd-EOB-DTPA (EOB·Primovist®) for low-field magnetic resonance imaging of canine focal liver lesions.
Yonetomi D; Kadosawa T; Miyoshi K; Nakao Y; Homma E; Hanazono K; Yamada E; Nakamura K; Ijiri A; Minegishi N; Maetani S; Hirayama K; Taniyama H; Nakade T
Vet Radiol Ultrasound; 2012; 53(4):371-80. PubMed ID: 22548505
[TBL] [Abstract][Full Text] [Related]
2. Primovist, Eovist: what to expect?
Van Beers BE; Pastor CM; Hussain HK
J Hepatol; 2012 Aug; 57(2):421-9. PubMed ID: 22504332
[TBL] [Abstract][Full Text] [Related]
3. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers.
Brismar TB; Dahlstrom N; Edsborg N; Persson A; Smedby O; Albiin N
Acta Radiol; 2009 Sep; 50(7):709-15. PubMed ID: 19701821
[TBL] [Abstract][Full Text] [Related]
4. Contrast enhanced liver MRI in patients with primary sclerosing cholangitis: inverse appearance of focal confluent fibrosis on delayed phase MR images with hepatocyte specific versus extracellular gadolinium based contrast agents.
Husarik DB; Gupta RT; Ringe KI; Boll DT; Merkle EM
Acad Radiol; 2011 Dec; 18(12):1549-54. PubMed ID: 21958599
[TBL] [Abstract][Full Text] [Related]
5. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA.
Vogl TJ; Kümmel S; Hammerstingl R; Schellenbeck M; Schumacher G; Balzer T; Schwarz W; Müller PK; Bechstein WO; Mack MG; Söllner O; Felix R
Radiology; 1996 Jul; 200(1):59-67. PubMed ID: 8657946
[TBL] [Abstract][Full Text] [Related]
6. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
[TBL] [Abstract][Full Text] [Related]
7. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma].
Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC
Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944
[TBL] [Abstract][Full Text] [Related]
8. A case of Budd-Chiari syndrome: Gd-EOB-DTPA-enhanced MR findings.
Kitajima K; Yoshikawa T; Seo Y; Ohno Y; Yano Y; Miki A; Kanda T; Kanata N; Azuma T; Sugimura K
Magn Reson Imaging; 2011 May; 29(4):579-83. PubMed ID: 21216550
[TBL] [Abstract][Full Text] [Related]
9. [Renal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPA].
Zangos S; Hammerstingl R; Mack MG; Straub R; Engelmann K; Eichler K; Balzer T; Vogl TJ
Rofo; 2001 Nov; 173(11):1034-40. PubMed ID: 11704914
[TBL] [Abstract][Full Text] [Related]
10. Comparison of three different injection methods for arterial phase of Gd-EOB-DTPA enhanced MR imaging of the liver.
Tamada T; Ito K; Yoshida K; Kanki A; Higaki A; Tanimoto D; Higashi H
Eur J Radiol; 2011 Dec; 80(3):e284-8. PubMed ID: 21296514
[TBL] [Abstract][Full Text] [Related]
11. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
[TBL] [Abstract][Full Text] [Related]
12. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA.
Tamada T; Ito K; Sone T; Yamamoto A; Yoshida K; Kakuba K; Tanimoto D; Higashi H; Yamashita T
J Magn Reson Imaging; 2009 Mar; 29(3):636-40. PubMed ID: 19243060
[TBL] [Abstract][Full Text] [Related]
13. Gadolinium-ethoxybenzyl-DTPA, a new liver-specific magnetic resonance contrast agent. Kinetic and enhancement patterns in normal and cholestatic rats.
Clément O; Mühler A; Vexler V; Berthezène Y; Brasch RC
Invest Radiol; 1992 Aug; 27(8):612-9. PubMed ID: 1428739
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
15. Dilution method of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI).
Motosugi U; Ichikawa T; Sou H; Sano K; Ichikawa S; Tominaga L; Araki T
J Magn Reson Imaging; 2009 Oct; 30(4):849-54. PubMed ID: 19787734
[TBL] [Abstract][Full Text] [Related]
16. Comparison between areas with Gd-EOB-DTPA uptake and without in hepatocellular carcinomas on Gd-EOB-DTPA-enhanced hepatobiliary-phase MR imaging: pathological correlation.
Lee S; Kim SH; Park CK; Kim YS; Lee WJ; Lim HK
J Magn Reson Imaging; 2010 Sep; 32(3):719-25. PubMed ID: 20815073
[TBL] [Abstract][Full Text] [Related]
17. Early phase detection of bile leak after hepatobiliary surgery: value of Gd-EOB-DTPA-enhanced MR cholangiography.
Alegre Castellanos A; Molina Granados JF; Escribano Fernandez J; Gallardo Muñoz I; Triviño Tarradas Fde A
Abdom Imaging; 2012 Oct; 37(5):795-802. PubMed ID: 22213118
[TBL] [Abstract][Full Text] [Related]
18. Hepatic parenchymal enhancement at Gd-EOB-DTPA-enhanced MR imaging: correlation with morphological grading of severity in cirrhosis and chronic hepatitis.
Kanki A; Tamada T; Higaki A; Noda Y; Tanimoto D; Sato T; Higashi H; Ito K
Magn Reson Imaging; 2012 Apr; 30(3):356-60. PubMed ID: 22227353
[TBL] [Abstract][Full Text] [Related]
19. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers.
Tamada T; Ito K; Higaki A; Yoshida K; Kanki A; Sato T; Higashi H; Sone T
Eur J Radiol; 2011 Dec; 80(3):e311-6. PubMed ID: 21315529
[TBL] [Abstract][Full Text] [Related]
20. Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging.
Higaki A; Tamada T; Sone T; Kanki A; Sato T; Tanimoto D; Higashi H; Ito K
Magn Reson Imaging; 2012 Jun; 30(5):689-93. PubMed ID: 22459437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
